Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for vertigo and equilibrium ...
Eisai Co., Ltd. announced today that “NouKNOW®”, Eisai’s self-check tool for brain health, was certified as a “ME-BYO BRAND” ...
Around 14 months after Eisai and Biogen’s Leqembi was filed for approval in the EU, the bloc’s regulatory authority has ...
The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.
Japanese drugmaker Eisai on Thursday said the distribution of its Alzheimer's drug Leqembi in the United States has proceeded ...
In navigating the Alzheimer's disease crisis, primary care providers should play key roles in cognitive testing and ...
Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd (OTC:ESALF) (OTC:ESALY) faced a setback as the much-anticipated Oral Explanation ...
The European Union's medicines regulator has delayed its decision on Eisai and partner Biogen's Alzheimer's disease drug that ...
Europe may still await its first disease-modifying Alzheimer’s drug after the EMA postponed its decision on Leqembi ...
During the last three months, 18 analysts shared their evaluations of Biogen (NASDAQ:BIIB), revealing diverse outlooks from ...
DeCarli reported serving as a consultant to Novartis on a safety study of heart failure during the conduct of the study and ...
Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.